Literature DB >> 12086861

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Jodi K Maranchie1, James R Vasselli, Joseph Riss, Juan S Bonifacino, W Marston Linehan, Richard D Klausner.   

Abstract

Clear-cell renal carcinoma is associated with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL is the substrate recognition subunit of an E3 ligase, known to target the alpha subunits of the HIF heterodimeric transcription factor for ubiquitin-mediated degradation under normoxic conditions. We demonstrate that competitive inhibition of the VHL substrate recognition site with a peptide derived from the oxygen degradation domain of HIF1alpha recapitulates the tumorigenic phenotype of VHL-deficient tumor cells. These studies prove that VHL substrate recognition is essential to the tumor suppressor function of VHL. We further demonstrate that normoxic stabilization of HIF1alpha alone, while capable of mimicking some aspects of VHL loss, is not sufficient to reproduce tumorigenesis, indicating that it is not the critical oncogenic substrate of VHL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12086861     DOI: 10.1016/s1535-6108(02)00044-2

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  162 in total

Review 1.  Renal cancer: oxygen meets metabolism.

Authors:  Volker H Haase
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

Review 2.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 3.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

4.  Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.

Authors:  Hongxia Z Imtiyaz; Emily P Williams; Michele M Hickey; Shetal A Patel; Amy C Durham; Li-Jun Yuan; Rachel Hammond; Phyllis A Gimotty; Brian Keith; M Celeste Simon
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 5.  The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Authors:  Lili Liao; Joseph R Testa; Haifeng Yang
Journal:  Cancer Genet       Date:  2015-02-20

Review 6.  Oncogenes strike a balance between cellular growth and homeostasis.

Authors:  Bo Qiu; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

7.  pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.

Authors:  In-Young Hwang; Jae-Seok Roe; Ja-Hwan Seol; Hwa-Ryeon Kim; Eun-Jung Cho; Hong-Duk Youn
Journal:  Mol Cells       Date:  2012-02       Impact factor: 5.034

8.  Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.

Authors:  William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin
Journal:  EMBO J       Date:  2006-09-14       Impact factor: 11.598

9.  Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.

Authors:  Tetsuhiro Tanaka; Junna Yamaguchi; Kumi Shoji; Masaomi Nangaku
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

10.  Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Authors:  Jessica A Bertout; Shetal A Patel; Benjamin H Fryer; Amy C Durham; Kelly L Covello; Kenneth P Olive; Michael H Goldschmidt; M Celeste Simon
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.